for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Resverlogix Corp.

RVX.TO

Latest Trade

1.46CAD

Change

-0.02(-1.35%)

Volume

118,198

Today's Range

1.33

 - 

1.54

52 Week Range

0.35

 - 

4.94

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1.48
Open
1.54
Volume
118,198
3M AVG Volume
4.05
Today's High
1.54
Today's Low
1.33
52 Week High
4.94
52 Week Low
0.35
Shares Out (MIL)
209.42
Market Cap (MIL)
305.50
Forward P/E
-4.20
Dividend (Yield %)
--

Next Event

Resverlogix Corp at Biotechnology Industry Organization (BIO) Investor Forum Conference

Latest Developments

More

Resverlogix Announces Topline Results In Betonmace Phase 3 Epigenetics Trial

Resverlogix Provides Update On Betonmace Phase 3 Trial

Eastern Capital Exercised Warrants To Acquire 5 Mln Shares Of Resverlogix At Cash Price Of C$0.75/Share, For Total Consideration Of C$3.75 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Resverlogix Corp.

Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's disease, Fabry disease, other orphan diseases, and peripheral artery disease. Apabetalone is being studied in a Phase III trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Industry

Biotechnology & Drugs

Contact Info

300-4820 Richard Rd SW

+1.403.2549252

https://www.resverlogix.com/

Executive Leadership

Donald J. McCaffrey

Chairman of the Board, President, Chief Executive Officer, Secretary

A. Brad Cann

Chief Financial Officer

Jan O. Johansson

Senior Vice President - Medical Affairs

Kenneth Lebioda

Senior Vice President - Business & Corporate Development

Michael T. Sweeney

Senior Vice President - Clinical Development

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-0.420

2019

-0.900

2020(E)

-0.265
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
-639.14

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up